Pulse signal therapy
can be employed in the management of patellofemoral pain syndrome with
chondropathy as it demonstrated significant efficacy up to 12 months.
People with patellar chondropathy and patellofemoral pain syndrome show effective outcomes with the treatment of pulsed signal therapy (PST) at three months, evident from a prospective randomized, double-blind placebo-controlled trial published in the Bioelectromagnetics.
Forty-one knees were selected and divided to received either nine 60-min daily sittings of PST treatment (PST group) or the similar protocol of blinded placebo treatment (placebo group). A change in Kujala score from baseline at three months was considered as the primary outcome. Participants of the placebo group obtain effective treatment after three months, after that both groups were followed for one year.
The PST group
exhibited significant improved Kujala points as compared to the placebo group
by the third month. Patients of PST group also exhibited progressive
improvements between the 3rd and 6th and between the 6th and 12th month;
whereas the patients of the control group showed improvement at 3rd and 6th
month. The improvements among PST-treated patients were progressive and
maintained up to one year. These findings reflect the PST is safe and effective
and can be used as a non-invasive approach for patellar chondropathy.
Bioelectromagnetics
Clinical results of pulsed signal therapy on patellofemoral syndrome with patellar chondropathy.
Riccardo Gomes Gobbi et al.
Comments (0)